免疫检查点抑制剂治疗癌症患者健康相关生活质量的随机对照试验系统综述与荟萃分析
该系统综述与荟萃分析纳入17项随机试验、8341例晚期实体瘤患者,比较免疫检查点抑制剂(ICI)与标准化疗(CT)的患者报告结局。ICI在EORTC QLQ-C30全球健康状况/生活质量及EQ-5D效用指数和视觉模拟评分上均延迟了临床恶化,且平均变化差异有利于ICI。结论认为ICI与更高质量生活和更长至临床恶化时间相关。
要点
- ICI较CT延迟EORTC QLQ-C30全球健康状况/QoL临床恶化(HR 0.81;95%CI 0.74-0.89)。
- ICI较CT延迟EQ-5D效用指数恶化(HR 0.65;95%CI 0.52-0.82)和VAS恶化(HR 0.70;95%CI 0.61-0.80)。
- ICI组与CT组平均变化差异为5.82(95%CI 4.11-7.53),有利于ICI。
核心结论
- 在多种实体瘤中,与CT相比,ICI与更高生活质量和多个PRO量表上更长至临床恶化时间相关。
研究设计与样本
- 系统综述与荟萃分析,纳入17项随机试验,共8341例接受ICI对比CT的晚期实体瘤患者。
- 纳入ICI(PD-1/PD-L1或CTLA-4抑制剂,单药或联合)对比CT的试验,以及ICI联合CT对比CT的试验;排除对照臂含其他抗癌药或单用安慰剂的试验。
- 共同主要终点为基线至PRO首次临床显著恶化的时间和基线至随访PRO变化。
- PROSPERO注册号CRD42021247440。
主要发现
- ICI较CT延迟EORTC QLQ-C30全球健康状况/QoL临床恶化(HR 0.81;95%CI 0.74-0.89)。
- ICI较CT延迟EQ-5D效用指数恶化(HR 0.65;95%CI 0.52-0.82)。
- ICI较CT延迟EQ-5D视觉模拟评分(VAS)恶化(HR 0.70;95%CI 0.61-0.80)。
- ICI组与CT组平均变化差异为5.82(95%CI 4.11-7.53),有利于ICI。
- EQ-5D效用指数和VAS的平均变化差异分别为0.05(95%CI 0.03-0.07)和5.41(95%CI 3.39-7.43),均有利于ICI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionised clinical practice in oncology in the last years, leading to a survival benefit in several tumour types. To investigate whether these benefits are associated with improved quality of life, we conducted a systematic review and meta-analysis comparing patient-reported outcomes (PROs) between ICIs and standard chemotherapy (CT) in patients with advanced solid tumours. METHODS: Clinical trials comparing the efficacy of ICIs (either programmed death receptor-1 and programmed death-ligand 1 inhibitors or cytotoxic T-lymphocyte antigen 4 inhibitors, as single agent or in combination) versus CT were included. Trials evaluating treatment with ICIs plus CT versus CT alone were also included, whereas studies in which the control arm included other anticancer agents (such as targeted therapy and other ICIs) or placebo alone were excluded. The aim of our meta-analysis was to compare PROs in subjects treated with ICIs or ICIs plus CT (intervention) with those reported by patients receiving CT (control). The co-primary endpoints were time from baseline to first deterioration in PROs, defined as the time from baseline to the first clinically significant deterioration in PROs, and the changes in PROs from baseline to follow-up between ICI and CT treatment groups (PROSPERO registration number CRD42021247440). RESULTS: A total of 8341 patients from 17 randomised trials of ICI versus CT were included in the analysis. Treatment with ICI delayed clinical deterioration over standard CT in Global Health Status/QoL EORTC QLQ-C30 (hazard ratio [HR] 0.81; 95% confidence interval [CI], 0.74-0.89), and in both EQ-5D utility index (HR 0.65; 95% CI, 0.52-0.82) and EQ-5D visual analogue scale (VAS; HR 0.70; 95% CI, 0.61-0.80). The difference in mean change between the ICI-treated group and the CT-treated group was 5.82 (95% CI, 4.11-7.53) in favour of ICI. Similarly, in the EQ-5D, the mean change differences favoured treatment with ICIs in both Utility Index and VAS, with differences of 0.05 (95% CI, 0.03-0.07) and 5.41 (95% CI, 3.39-7.43), respectively. CONCLUSIONS: ICIs are associated with higher levels of quality of life and longer time to clinical deterioration on several PROs scales compared with CT in different types of solid tumours.
引用
- Boutros A, Bruzzone M, Tanda ET, et al. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 34753012. doi:10.1016/j.ejca.2021.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。